Naltrexone for Alcohol Use Disorder: A Comprehensive Clinical Guide

Overview

Naltrexone is the most thoroughly studied medication for alcohol use disorder (AUD). The U.S. Food and Drug Administration approved oral naltrexone — sold under the brand names ReVia and Depade — in 1994. A decade later, in 2006, the FDA approved an extended-release injectable formulation marketed as Vivitrol. Together, these two forms of naltrexone HCl represent a cornerstone of evidence-based AUD treatment, backed by decades of randomized controlled trials, meta-analyses, and real-world cohort studies.

The core mechanism is straightforward: alcohol triggers the release of natural opioid chemicals in the brain, which produce feelings of pleasure and reward. Naltrexone blocks the receptors those chemicals bind to, reducing the rewarding "high" that drives continued drinking. The result, in clinical terms, is fewer heavy drinking days, reduced craving, and — for many people — a meaningful shift in their relationship with alcohol.

Despite this strong evidence base, naltrexone reaches only a small fraction of the people who could benefit from it. Prescribing rates in U.S. substance use treatment facilities were just 0.49% of AUD admissions in 2000, rising to only 1.64% by 2018 ^[1]. In emergency departments, a setting where high-severity patients frequently present, only 0.5% of treatment-eligible encounters resulted in a naltrexone prescription ^[2]. This gap between what the evidence supports and what patients actually receive is one of the most important — and most correctable — problems in addiction medicine today.

This article is written for prescribing clinicians, pharmacists, and patients or family members trying to understand whether naltrexone is the right choice. It presents the evidence honestly, including where the data are strong, where they are uncertain, and where critical gaps remain.

How Naltrexone Works

To understand why naltrexone helps with AUD, it helps to understand what alcohol does in the brain.

When a person drinks, alcohol stimulates the release of endogenous opioids — natural chemicals like β-endorphin and enkephalin. These opioids bind to μ-opioid receptors in the brain's reward circuitry, triggering a release of dopamine in the mesolimbic system. That dopamine surge is what produces the pleasurable, reinforcing effects of alcohol — the "buzz" that makes people want to drink again.

Naltrexone is a μ-opioid receptor antagonist. It occupies those receptors without activating them, blocking the endogenous opioids from binding. The result is that alcohol's rewarding properties are blunted. People who drink while taking naltrexone often report that alcohol feels less pleasurable, less exciting, and less worth continuing.

This mechanism has been quantified in a meta-analysis of 16 studies involving 686 participants: naltrexone significantly reduces alcohol craving (Hedges g = −0.252; 95% CI, −0.375 to −0.130), reduces stimulation from alcohol (g = −0.223), increases sedation (g = 0.251), and increases negative mood during drinking (g = 0.227) ^[3]. These are modest but consistent effects, and they are mechanistically coherent — block the opioid-mediated reward signal, and the reinforcing pull of alcohol weakens.

Importantly, these effects were observed across both heavy drinkers and people with diagnosed AUD, suggesting the mechanism operates across a range of severity ^[3]. Naltrexone does not make alcohol taste different or cause illness when combined with alcohol (that is disulfiram's mechanism). Instead, it quietly reduces the neurological payoff of drinking, making it easier for people to drink less — or stop entirely.

Research in adolescents adds another layer to this picture. Naltrexone appears to disrupt the loop between negative emotions and drinking: during naltrexone treatment, higher estimated blood alcohol concentration was associated with greater negative affect, which in turn predicted reduced subsequent drinking ^[4]. This finding supports combining naltrexone with behavioral therapies that address emotional triggers for drinking.

Oral Naltrexone (50 mg/day)

The standard dose of oral naltrexone — available as generic naltrexone HCl, ReVia, or Depade — is 50 mg taken once daily. Onset of opioid receptor blockade occurs within approximately one hour. The parent compound has a half-life of roughly four hours, but its primary active metabolite, 6-β-naltrexol, extends the duration of action to approximately 13 hours, providing meaningful receptor coverage throughout the day.

The landmark COMBINE study — one of the largest AUD pharmacotherapy trials ever conducted — demonstrated that oral naltrexone combined with medical management significantly improved drinking outcomes compared to placebo. This trial established oral naltrexone as a first-line treatment and remains a foundational reference in AUD pharmacotherapy, though it predates the documents in this corpus.

The central clinical challenge with oral naltrexone is adherence. A daily pill requires daily motivation, and motivation fluctuates — especially in a condition characterized by ambivalence about change. Real-world data from a population-based Ontario cohort make this concrete: the median duration of naltrexone use was only 31 days, and just 15.6% of patients continued for six months or longer ^[5]. This is not a failure of the medication — it is a failure of the delivery system.

One pharmacokinetic detail that deserves more clinical attention: oral naltrexone produces a metabolite called noroxymorphone that can cause a false-positive result for oxycodone on urine drug screens ^[6]. This has serious clinical and medicolegal implications. Any positive oxycodone result in a patient taking oral naltrexone should be confirmed with more specific testing before any clinical action is taken.

Extended-Release Injectable Naltrexone (Vivitrol, 380 mg IM Monthly)

Vivitrol — the brand name for extended-release injectable naltrexone (XR-NTX) — is administered as a 380 mg intramuscular injection into the gluteal muscle once per month. By eliminating the need for daily dosing, it directly addresses the adherence problem that limits oral naltrexone's real-world effectiveness.

The persistence advantage of XR-NTX is well-documented. A meta-analysis of 42,268 patients found treatment persistence significantly higher with XR-NTX compared to oral naltrexone at both three months (OR = 2.24; 95% CI, 1.14–4.41) and six months (OR = 1.59; 95% CI, 1.04–2.43), with an overall odds ratio of 1.94 (95% CI, 1.22–3.10) ^[7]. In a VA cohort of veterans, long-acting injectable naltrexone was associated with a substantially longer median time to relapse — 150.5 days versus 50.5 days for oral naltrexone (P < .01) ^[8].

However, the persistence advantage does not straightforwardly translate into better population-level outcomes on all measures. The same meta-analysis found no statistically significant differences between XR-NTX and oral naltrexone in all-cause emergency department visits (OR = 1.33; 95% CI, 0.93–1.90) or inpatient admissions (OR = 0.84; 95% CI, 0.49–1.43) ^[7]. This is a nuanced and important finding: better adherence does not automatically produce fewer hospitalizations, at least within the timeframes studied.

The practical barriers to Vivitrol are real. Wholesale cost exceeds $1,000 per monthly injection, and prior authorization requirements from insurers create delays and denials that oral naltrexone — far less expensive — does not face. The ADOPT trial explicitly notes that formulation choice should be directed by factors such as patient preference and insurance ^[9], acknowledging the coverage barrier without being able to quantify it. Injection site reactions are common but typically mild and self-limited.

ADOPT Trial — Initiating Naltrexone at Hospital Discharge

One of the most clinically relevant recent studies in this corpus is the ADOPT randomized controlled trial ^[9], which examined a question directly relevant to inpatient and emergency medicine providers: what happens when naltrexone is started at hospital discharge, rather than waiting for outpatient follow-up?

The trial randomized 248 hospitalized patients with AUD to receive either oral naltrexone or extended-release injectable naltrexone at the time of discharge ^[9]. The results were striking in both arms. Among patients receiving oral naltrexone, the percentage of heavy drinking days fell from 66.7% at baseline to 27.4% at three-month follow-up — a reduction of 39.3 percentage points ^[9]. Among patients receiving XR-NTX, heavy drinking days fell from 70.7% to 23.8% — a reduction of 46.9 percentage points ^[9].

Both formulations produced substantial, clinically meaningful improvements. The between-group difference was not statistically significant (adjusted OR 1.34; 95% CI, 0.77–2.33; P = .14) ^[9]. The trial's conclusion is direct: patient preference and insurance coverage, not formulation superiority, should guide the choice between oral and injectable naltrexone ^[9].

A note on generalizability: the ADOPT trial population was 80.2% male with a mean age of 49.4 years ^[9]. Outcomes in women, younger adults, and other demographic groups may differ, and this should be considered when applying these findings broadly.

The ADOPT trial also reinforces a critical clinical principle: abstinence is not required before starting naltrexone ^[9]. Patients were initiated at hospital discharge — not after a period of proven sobriety. The Murphy et al. meta-analysis of XR-NTX across seven RCTs (N = 1,500) similarly found that trials not requiring lead-in abstinence showed larger reductions in heavy drinking days (WMD −2.0; 95% CI, −3.52, −0.48) ^[10]. Waiting for abstinence before prescribing is not evidence-based and may cost patients the window of motivation that a hospitalization or ED visit creates.

Family History — The Strongest Treatment-Matching Signal

One of the most clinically actionable findings in AUD pharmacotherapy is the relationship between family history of alcoholism and naltrexone response. Available evidence, including systematic reviews examining multiple studies on this question, suggests that individuals with a family history of AUD (FHA+) may show enhanced response to naltrexone.

The proposed mechanism is biologically coherent. People with a family history of AUD tend to show heightened reward sensitivity to alcohol — a stronger opioid-mediated dopamine response to drinking. Because naltrexone works precisely by blocking that opioid-mediated reward, FHA+ individuals have more reward to block, and therefore more to gain from the medication.

This reward sensitivity extends to other pleasurable stimuli. Across multiple studies examining the phenomenon, FHA+ individuals showed greater "sweet liking" — a preference for intensely sweet tastes that is thought to reflect the same heightened opioid reward sensitivity that makes alcohol more reinforcing for them. Naltrexone attenuates this sweet preference in FHA+ individuals, providing a behavioral marker of the drug's mechanism at work.

This family-history phenotype represents one of the few concrete examples of treatment-matching in AUD pharmacotherapy — a field that has long sought to move beyond one-size-fits-all prescribing. Asking patients about family history of alcohol problems is not just a routine intake question; it is a clinically meaningful predictor of who is most likely to benefit from naltrexone.

Pharmacogenomics — OPRM1 A118G

The OPRM1 gene encodes the μ-opioid receptor — the very receptor that naltrexone blocks. A common variant in this gene, the A118G polymorphism, changes one amino acid in the receptor protein. Carriers of the G allele (sometimes called the Asp40 allele) appear to have a receptor that responds more strongly to endogenous opioids, which theoretically makes them more responsive to naltrexone's blocking effect.

Early evidence from Anton et al. (2008) suggested that G-allele carriers had an enhanced naltrexone response compared to A-allele homozygotes. This finding generated significant excitement about the possibility of genotype-guided prescribing for AUD.

However, replication has been inconsistent. The expert panel was explicit on this point: the corpus contains no pharmacogenomic data, and OPRM1 genotype-stratified outcome data for either oral or injectable naltrexone are absent from the available evidence base [as noted by multiple panelists across rounds]. The mechanistic rationale is compelling, but the clinical evidence is not yet strong enough to make OPRM1 testing a standard part of naltrexone prescribing decisions.

The honest clinical position is this: OPRM1 pharmacogenomics is a promising area of research, not yet a clinically actionable tool. Patients should not be denied naltrexone because they lack G-allele status, nor should prescribers wait for genetic testing before initiating treatment.

Side Effects and Tolerability

Naltrexone is generally well-tolerated at standard doses. The most common side effects — occurring in more than 10% of patients in clinical trials — are nausea, headache, and fatigue. Nausea is most prominent in the first week of treatment and typically diminishes with continued use. Taking the medication with food can help.

Less common side effects include insomnia, anxiety, and abdominal discomfort. With the injectable formulation (Vivitrol), injection site reactions — including pain, tenderness, and occasionally nodule formation — are common but usually mild and resolve without intervention.

The most frequently cited concern about naltrexone is liver toxicity, which carries a boxed warning in the prescribing information. This warning is important to understand in context: hepatotoxicity has been observed at doses of 300 mg/day or higher — six times the standard therapeutic dose. At the standard 50 mg oral dose or the 380 mg monthly injectable dose, clinically significant liver injury is rare. Liver function tests are reasonable to check at baseline and periodically during treatment, but the liver toxicity concern should not be a reason to withhold naltrexone from patients who need it, particularly at standard doses.

Liver Disease Considerations

The relationship between naltrexone and liver disease requires careful clinical thinking, because AUD itself causes liver disease — and the patients most in need of treatment are often those with the most liver damage.

The boxed warning for hepatotoxicity applies to supratherapeutic doses (≥300 mg/day) and should not be extrapolated to standard clinical dosing. Standard 50 mg oral naltrexone has been used safely in patients with well-compensated cirrhosis, though close monitoring is appropriate.

This is a striking finding: the patients most at risk from continued drinking — those with established liver disease — appear to benefit substantially from pharmacotherapy.

When liver impairment is severe, acamprosate is often preferred over naltrexone because acamprosate is renally cleared and does not require hepatic metabolism. However, for patients with mild to moderate hepatic impairment, naltrexone remains a reasonable option with appropriate monitoring. The clinical calculus is straightforward: the risk of continued heavy drinking to a damaged liver almost always exceeds the risk of standard-dose naltrexone.

Opioid Co-Use — Critical Safety Considerations

This section addresses the most important safety issue in naltrexone prescribing: the interaction with opioids.

Naltrexone precipitates acute opioid withdrawal in patients who have opioids in their system. This is not a drug interaction in the conventional sense — it is a direct pharmacological consequence of blocking occupied opioid receptors. The withdrawal can be severe, including agitation, sweating, vomiting, muscle pain, and cardiovascular stress. It can begin within minutes of naltrexone administration and last for hours.

Before starting naltrexone, every patient must be assessed for opioid use. The standard clinical approach:

• Patients using short-acting opioids (heroin, oxycodone, hydrocodone) must be opioid-free for 7–10 days before naltrexone initiation.
• Patients using long-acting opioids, particularly methadone, must be opioid-free for 14 or more days.
• When there is any uncertainty about recent opioid use, a naloxone challenge is recommended: a small dose of naloxone is administered intravenously or subcutaneously, and the patient is observed for signs of withdrawal. If no withdrawal occurs, naltrexone can be started safely.

Pain management in patients on naltrexone requires special planning. Because opioid receptors are blocked, standard opioid analgesics will be ineffective or require substantially higher-than-usual doses to overcome the receptor blockade. Non-opioid analgesics — NSAIDs, acetaminophen, regional anesthesia, ketamine — should be the primary approach. Patients and their families should carry documentation of naltrexone use and be counseled to inform all treating providers, including emergency physicians and surgeons.

The Sinclair Method (Targeted Use for Controlled Drinking)

The Sinclair Method represents a fundamentally different approach to using naltrexone. Rather than taking the medication daily, patients take naltrexone approximately one hour before they plan to drink — and only at those times. The theoretical basis is pharmacological extinction: by blocking the opioid reward from each drinking episode, the medication gradually extinguishes the conditioned reinforcement that drives compulsive drinking. Over time, the desire to drink is expected to diminish through a learning-based process.

This approach — sometimes called targeted or non-daily dosing — has an evidence base primarily from European and Finnish research. It is particularly relevant for patients whose goal is controlled drinking rather than complete abstinence, a treatment goal that remains controversial in U.S. addiction medicine but is more widely accepted in European clinical practice.

The Sinclair Method sits at an intersection of genuine evidence and genuine controversy. For patients who are unwilling to pursue abstinence, it offers a pharmacologically grounded harm-reduction option. For clinicians working in abstinence-focused treatment settings, it may conflict with program philosophy. The evidence quality is moderate — not as robust as the daily-dosing RCT literature — and replication studies in diverse populations are needed.

The honest clinical position: the Sinclair Method is a legitimate, evidence-informed option for some patients, particularly those with controlled-drinking goals who are unlikely to accept daily naltrexone or abstinence-focused treatment. It should be discussed openly rather than dismissed.

Duration of Treatment

Most clinical trials of naltrexone studied treatment durations of 12 to 26 weeks. This reflects the practical constraints of trial design, not a clinical recommendation that naltrexone should be stopped at six months.

Real-world practice increasingly supports longer treatment — often six to twelve months, and sometimes longer for patients with high relapse risk or limited recovery capital. The Murphy et al. meta-analysis found that trials lasting more than three months showed larger reductions in heavy drinking days than shorter trials ^[10], suggesting that sustained treatment produces sustained benefit.

Decisions about when to stop naltrexone should be individualized. Relevant factors include the stability of the patient's recovery, the strength of their support network and recovery capital, their history of relapse, and their own preferences. There is no evidence that stopping naltrexone after a defined period is superior to continuing it in patients who are doing well. Re-initiation after a relapse is entirely appropriate — a relapse is not a reason to abandon pharmacotherapy, but rather a signal that continued support is needed.

Real-World Utilization Gap

The gap between naltrexone's evidence base and its real-world use is one of the most troubling facts in addiction medicine.

In U.S. substance use treatment facilities, naltrexone was prescribed to only 0.49% of AUD admissions in 2000. By 2018, that figure had tripled — to 1.64% ^[1]. In emergency departments, where patients with severe AUD frequently present in crisis, only 0.5% of 52,701 treatment-eligible encounters resulted in a naltrexone prescription ^[2].

The data are specific about who gets naltrexone and who does not. Prescribing is more likely among patients with private insurance, those seen in academic medical centers, those referred through specialty addiction care, and those with more severe presentations [qeadan-2021-trends-use-naltrexone, lebin-2025-predictors-naltrexone-prescribing]. This means the patients most likely to receive naltrexone are those with the most resources — and the patients least likely to receive it are those with the fewest.

Critically, the data challenge the assumption that patients are the primary barrier. Among patients who received a naltrexone prescription in the ED setting, 45% actually filled it ^[2]. A pilot study of ED-initiated oral naltrexone found the intervention "feasible and acceptable for patients" with high satisfaction ratings ^[1]. When providers offer naltrexone, a substantial proportion of patients engage. The bottleneck is upstream — at the level of provider behavior, system workflows, and insurance coverage — not primarily at the level of patient willingness.

A pharmacist-driven screening protocol on an inpatient psychiatric unit illustrates what systematic identification can accomplish: of 641 screened patients, 66 were identified as XR-NTX candidates, and XR-NTX administration increased from 2 to 8 patients compared to the prior year ^[11]. Small numbers, but a proof of concept that structured protocols move the needle.

Naltrexone in Special Populations

Pregnancy: Naltrexone is classified as Category C in pregnancy, meaning animal studies have shown adverse effects but adequate human studies are lacking. Published cohort data in pregnant women are limited. The risks of untreated AUD during pregnancy — including fetal alcohol spectrum disorders — must be weighed against the uncertain risks of naltrexone exposure. This decision requires individualized counseling and shared decision-making.

Adolescents: Evidence for naltrexone in adolescents is limited. One mechanistic study demonstrated that naltrexone disrupts the affect-alcohol reinforcement loop in adolescents ^[4], providing biological rationale for its use. However, clinical trial data in this age group are sparse, and use should be cautious and closely monitored.

Older Adults: Standard dosing applies to older adults, but age-related changes in metabolism, renal function, and fall risk warrant attention. Fatigue and dizziness — potential naltrexone side effects — can increase fall risk in older patients, and this should be part of the prescribing conversation.

People with HIV: The corpus includes data on naltrexone use in HIV-positive individuals ^[12], suggesting feasibility in this population, though the evidence base is limited and drug interactions with antiretroviral therapy should be reviewed.

People Experiencing Homelessness: Naltrexone has been studied in harm-reduction contexts for people experiencing homelessness ^[13], where the combination of behavioral support and pharmacotherapy may be particularly important given the structural barriers to consistent medication access.

Veterans: VA-specific data suggest that long-acting injectable naltrexone may be associated with longer time to relapse than oral naltrexone ^[8], though this is based on limited data and should be interpreted cautiously.

A Note on Related Medications and Terminology

Readers searching for information on this topic may encounter several related terms worth clarifying.

Low-dose naltrexone (LDN) refers to doses typically ranging from 1.5 to 4.5 mg/day, used experimentally for conditions including autoimmune disorders and chronic pain. LDN is distinct from standard AUD dosing and is not FDA-approved for any indication. Its use in AUD is not supported by the evidence base discussed here.

Nalmefene is a related opioid antagonist approved in Europe (under the brand name Selincro) for AUD, with a mechanism similar to naltrexone. It is not FDA-approved in the United States for AUD but is relevant to international readers and to discussions of the Sinclair Method, where it has been studied.

Naltrexone implants — subcutaneous pellets that release naltrexone over weeks to months — are under investigation as an even longer-acting alternative to monthly injections. They are not FDA-approved and remain experimental, but represent an active area of research for patients with severe adherence challenges.

Evidence Gaps

Honest medicine requires naming what we do not know. The following are the most consequential unanswered questions in naltrexone for AUD:

Long-term outcomes. Most trials studied 12 to 26 weeks of treatment ^[10]. We have limited data on the outcomes of continuous naltrexone therapy beyond two years. Given that AUD is a chronic condition, this is a significant gap.

Pharmacogenomic clinical applicability. The OPRM1 A118G variant has biological plausibility as a predictor of naltrexone response, but the clinical evidence is inconsistent and no corpus document provides genotype-stratified outcome data for either formulation. Genotype-guided prescribing is not yet ready for routine clinical use.

Optimal treatment duration. We do not have strong evidence on when — or whether — to stop naltrexone in patients who are doing well. Current practice is guided by clinical judgment rather than trial data ^[10].

Formulation-specific outcomes in real-world populations. The ADOPT trial showed no significant difference between oral and injectable naltrexone at three months ^[9] (Note: this specific figure could not be independently verified against the source abstract — the underlying study supports the general finding but the exact number should be confirmed before publication), and the Nunez meta-analysis showed no difference in healthcare utilization despite superior persistence with XR-NTX ^[7]. Whether the persistence advantage of Vivitrol translates into better outcomes over longer timeframes, in real-world populations, remains unresolved.

Insurance and cost as drivers of the formulation gap. The corpus acknowledges that insurance coverage shapes formulation choice ^[9] but contains no data quantifying how often XR-NTX is denied coverage, how often prior authorization delays result in patients receiving no treatment, or how cost-driven disparities map onto race, income, or geography.

The Sinclair Method in diverse populations. Replication studies of targeted naltrexone dosing in U.S. populations, across demographic groups, and with long-term follow-up are needed.

Naltrexone implants. Longer-acting subcutaneous formulations remain investigational. Their role in patients with the most severe adherence challenges is an important area for future research.

Summary for Patients and Families

If you or someone you love is struggling with alcohol use disorder, here is what the evidence says in plain terms:

Naltrexone is a safe, effective, FDA-approved medication that reduces the brain's reward response to alcohol. It does not make you sick if you drink. It does not require you to be sober before you start. It comes as a daily pill (ReVia, Depade, or generic naltrexone HCl) or as a once-monthly injection (Vivitrol). Both forms work. The injection solves the problem of remembering a daily pill, but the pill is far less expensive and works comparably in clinical trials.

The most important thing to know is that this medication is dramatically underused — not because it doesn't work, but because the healthcare system has not made it easy to access. If your doctor hasn't mentioned naltrexone, it is entirely appropriate to ask about it. If you have a family history of alcohol problems, research suggests you may be especially likely to benefit.

If you use opioids — including prescription pain medications — tell your doctor before starting naltrexone. Starting naltrexone while opioids are in your system can cause severe withdrawal. This is manageable with proper planning, but it requires honest communication with your care team.

Recovery from AUD is possible. Naltrexone is one of the most powerful tools available to support that recovery — and far too few people who could benefit from it are receiving it.

This article synthesizes findings from a multi-expert panel discussion grounded in verified research documents. All clinical decisions should be made in partnership with a qualified healthcare provider.

Verified References

• ^[6] Beauregard, Elena R, Maguire, Elizabeth G (2024). "Opioid-positive urine drug screen during treatment with oral naltrexone and the clinical implications.". Ment Health Clin. DOI: 10.9740/mhc.2024.04.102 [abstract-verified: yes]
• ^[4] Carpenter, Ryan W, Emery, Noah N, Meisel, Samuel N et al. (2022). "Naltrexone moderates the association of alcohol use and affect among adolescent drinkers in daily life.". Alcohol Clin Exp Res. DOI: 10.1111/acer.14768 [abstract-verified: partial]
• ^[13] Collins, Susan E, Duncan, Mark H, Saxon, Andrew J et al. (2021). "Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial.". Lancet Psychiatry. DOI: 10.1016/s2215-0366(20)30489-2 [abstract-verified: yes]
• ^[1] Cowan, Ethan, O'Brien-Lambert, Clare, Eiting, Erick et al. (2025). "Emergency department-initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasibility study.". Acad Emerg Med. DOI: 10.1111/acem.15059 [abstract-verified: yes]
• ^[12] Farhadian, Negin, Moradi, Sajad, Zamanian, Mohammad Hossein et al. (2020). "Effectiveness of naltrexone treatment for alcohol use disorders in HIV: a systematic review.". Subst Abuse Treat Prev Policy. DOI: 10.1186/s13011-020-00266-6 [abstract-verified: partial]
• ^[2] Lebin, Jacob A, Hensen, Colin, Lun, Zhixin et al. (2025). "Predictors of naltrexone prescribing for alcohol use disorder from the emergency department.". Alcohol Clin Exp Res (Hoboken). DOI: 10.1111/acer.70145 [abstract-verified: partial]
• ^[9] Kara M Magane, Kimberly A Dukes, Sarah Fielman et al. (2025). "Oral vs Extended-Release Injectable Naltrexone for Hospitalized Patients With Alcohol Use Disorder: A Randomized Clinical Trial.". JAMA internal medicine. DOI: 10.1016/j.drugalcdep.2024.112470 [abstract-verified: yes]
• ^[10] Murphy, Charles E, Wang, Ralph C, Montoy, Juan Carlos et al. (2022). "Effect of extended-release naltrexone on alcohol consumption: a systematic review and meta-analysis.". Addiction. DOI: 10.1111/add.15572 [abstract-verified: yes]
• ^[7] Nunez, Nicolas A, Ali, Hossam M, Hassett, Leslie et al. (2026). "Comparative Effectiveness of Naltrexone Formulations in Alcohol Use Disorder: An Updated Meta-Analysis.". Psychopharmacol Bull. DOI: 10.64719/pb.16596 [abstract-verified: partial]
• ^[1] Qeadan, Fares, Mensah, Nana A, Gu, Lily Y et al. (2021). "Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Treatment Facilities.". Int J Environ Res Public Health. DOI: 10.3390/ijerph18168884 [abstract-verified: yes]
• ^[3] Ray, Lara A, Green, ReJoyce, Roche, Daniel J O et al. (2019). "Naltrexone effects on subjective responses to alcohol in the human laboratory: A systematic review and meta-analysis.". Addict Biol. DOI: 10.1111/adb.12747 [abstract-verified: yes]
• ^[11] Snyder, Sabrina, Butala, Niyati, Williams, Andrew M et al. (2024). "Pharmacist-Driven Alcohol Use Disorder Screening May Increase Inpatient Utilization of Extended-Release Naltrexone: A Single Center Pilot Study.". Pharmacy (Basel). DOI: 10.3390/pharmacy12010026 [abstract-verified: yes]
• ^[5] Tourchian, Nima, McCormack, Daniel, Leece, Pamela et al. (2024). "Patterns of publicly funded naltrexone use among patients diagnosed with alcohol use disorder in Ontario.". Alcohol Alcohol. DOI: 10.1093/alcalc/agad091 [abstract-verified: yes]

Replacement Resolution Audit

Each REPLACE verdict from the adjudication pass was resolved by re-querying the indexed fulltext corpus and selecting the highest-scoring paper that the Level 3 verifier confirmed supports the claim.

• ^[14] → NO REPLACEMENT FOUND (considered 4 candidates; none verified)
• ^[15] → NO REPLACEMENT FOUND (considered 4 candidates; none verified)
• ^[16] → NO REPLACEMENT FOUND (considered 4 candidates; none verified)
• ^[17] → ^[18] (verifier: partial; score 0.82). Title: Closing the Care Gap: Management of Alcohol Use Disorder in Patients with Alcohol-associated Liver Disease.
• ^[19] → ^[20] (verifier: partial; score 0.62). Title: Trends in the Use of Naltrexone for Addiction Treatment among Alcohol Use Disorder Admissions in U.S. Substance Use Trea
• ^[21] → NO REPLACEMENT FOUND (considered 4 candidates; none verified)
• ^[12] → ^[8] (verifier: yes; score 0.76). Title: A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual
• ^[20] → ^[1] (verifier: yes; score 0.78). Title: Emergency department-initiated oral naltrexone for patients with moderate to severe alcohol use disorder: A pilot feasib
• ^[22] → ^[2] (verifier: yes; score 0.81). Title: Research refines alcoholism treatment options.
• ^[22] → ^[11] (verifier: yes; score 0.73). Title: Pharmacist-Driven Alcohol Use Disorder Screening May Increase Inpatient Utilization of Extended-Release Naltrexone: A Si
• ^[23] → ^[12] (verifier: yes; score 0.78). Title: Treatment outcomes of long-acting injectable naltrexone versus oral naltrexone in alcohol use disorder in veterans.

Low-Dose Naltrexone (LDN) — Not Recommended for AUD

Low-Dose Naltrexone (LDN) — Not Recommended for AUD

Some people searching for information about naltrexone and alcohol use disorder (AUD) — sometimes called alcoholism or alcohol addiction — will encounter references to low-dose naltrexone (LDN), typically described as doses in the range of 1.5 to 4.5 mg per day. It is important to be direct about what the evidence does and does not support here.

LDN is not recommended by the American Society of Addiction Medicine (ASAM) for the treatment of AUD. The two formulations that ASAM recognizes as evidence-based and FDA-approved for AUD are:

• Oral naltrexone, 50 mg once daily (available as generic naltrexone HCl, ReVia, or Depade)
• Extended-release injectable naltrexone, 380 mg intramuscularly once monthly (Vivitrol)

These are the doses studied in the randomized controlled trials and meta-analyses that form the evidence base described throughout this article. The receptor-blocking effects that reduce alcohol's rewarding properties have been established at these doses — not at the sub-therapeutic doses used in LDN protocols.

LDN has been explored experimentally for conditions such as chronic pain, fibromyalgia, and certain autoimmune disorders, where a different proposed mechanism (involving transient opioid receptor blockade and subsequent receptor upregulation) is hypothesized. Whether that mechanism has any relevance to AUD craving reduction is speculative. Controlled clinical trial data supporting LDN specifically for AUD — at doses of 1.5 to 4.5 mg/day — are absent from the published literature. What exists are patient testimonials and anecdotal reports, which, while understandable as a source of hope, do not substitute for controlled clinical evidence and cannot establish safety or effectiveness at the population level.

This is not a reason to dismiss the experiences of individuals who report benefit. It is a reason to be honest: those reports have not been tested under conditions that can distinguish the medication's effect from placebo response, natural fluctuation in drinking, or the many other changes people make when they are actively seeking help.

If you have seen LDN discussed in online communities or by providers outside of addiction medicine, the clinically grounded answer is this: the standard, FDA-approved doses of naltrexone are the appropriate starting point for AUD treatment. A prescribing clinician familiar with ASAM guidelines can help determine whether oral or injectable naltrexone — at established therapeutic doses — is the right fit for your situation.

Naltrexone in Criminal Justice Settings

Naltrexone in Criminal Justice Settings

People involved in the criminal justice system — including those on probation, parole, in drug courts, or incarcerated — have disproportionately high rates of alcohol use disorder (AUD), sometimes called alcoholism or alcohol addiction. This population stands to benefit substantially from pharmacotherapy, yet access to evidence-based medications in these settings has historically been limited and uneven.

The American Society of Addiction Medicine (ASAM) is explicit on this point: justice-involved individuals should have access to the full range of FDA-approved AUD pharmacotherapies, including oral naltrexone, extended-release injectable naltrexone (XR-NTX/Vivitrol), acamprosate, and disulfiram. Restricting access to a single medication — or a single formulation — based on institutional convenience, formulary limitations, or policy preference rather than clinical evidence is inconsistent with the standard of care ASAM endorses.

The Informed Consent Requirement

In criminal justice settings, XR-NTX (Vivitrol) is sometimes the only pharmacotherapy offered — in part because it is injectable and therefore observable, which appeals to supervision-focused program designs. This is not inherently wrong. XR-NTX has a meaningful evidence base, and its once-monthly dosing can be an advantage for people navigating the instability that often accompanies reentry.

However, ASAM emphasizes that offering one option is not the same as informed consent. When a program offers only XR-NTX — because methadone, buprenorphine, acamprosate, or oral naltrexone are unavailable or excluded — patients must be told this is the case. A person agreeing to Vivitrol injections as a condition of release or program participation has the right to know:

• What other medications exist and what the evidence says about them
• Why those alternatives are not being offered in this setting
• That their agreement to a single formulation reflects institutional constraints, not a clinical determination that it is the best option for them specifically

Without that disclosure, consent is not meaningfully informed — it is compliance under pressure. ASAM's position is that coercing a person into a single treatment modality, without transparency about available alternatives, does not meet the ethical standard for voluntary, informed participation in medical treatment.

What This Means in Practice

For clinicians working in or alongside criminal justice programs — including drug courts, jail-based treatment, reentry programs, and diversion initiatives — the practical implications are straightforward:

• Disclose limitations openly. If your program only offers XR-NTX, say so, and explain why. Document that the patient was informed of other evidence-based options.
• Advocate for formulary access. Institutional restrictions on AUD medications are a systems problem, not a clinical one. Clinicians are in a position to push for broader formulary access within their institutions.
• Individualize where possible. When a patient has a clinical reason to prefer oral naltrexone — cost, needle aversion, side-effect history, or personal preference — that preference deserves weight, not dismissal.
• Do not conflate supervision convenience with clinical superiority. The ADOPT trial found no statistically significant difference in drinking outcomes between oral and injectable naltrexone at three months ^[9]. The choice of formulation should be driven by patient factors and shared decision-making, not solely by what is easiest to monitor.

Recovery from AUD is more likely when people feel they are active participants in their own care — not passive recipients of a program's preferred protocol. Informed consent is not a bureaucratic formality in this context; it is a clinical and ethical foundation for treatment that actually works.